FAP immunosuppressive CAR-DC

Phase 1Biologic

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

FAP immunosuppressive CAR-DC is one of 61 biologic programs targeting Acute Myocardial Infarction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

Dilated Cardiomyopathy (DCM)Recruiting

Dilated CardiomyopathyActive, not recruiting

Acute Myocardial InfarctionPhase 1

Active, not recruiting

Dilated Cardiomyopathy (DCM)Phase 1

Recruiting

Dilated CardiomyopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

4 2

Lovenox

Sanofi

Phase 3

2 3

Adenocard

Astellas

Phase 3

2 4

Lovenox

Sanofi

Phase 3

1 5

Aldactone

Pfizer

Phase 3

1 6

Byetta

AstraZeneca

Phase 3

1 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

3 8

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 9

Reopro

Boehringer Ingelheim

Phase 3

1 10

Allegra

CChattem

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Acute Myocardial Infarction

NCT07380659

Q4 2027

Phase 1Recruiting

Dilated Cardiomyopathy (DCM)

NCT07516288

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FAP immunosuppressive CAR-DC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FAP immunosuppressive CAR-DC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FAP immunosuppressive CAR-DC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

FAP immunosuppressive CAR-DC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Acute Myocardial Infarction1 trial

Dilated Cardiomyopathy1 trial

Dilated Cardiomyopathy (DCM)1 trial

References

Drug Info

Quick Facts

Related News